- Home
- NIE vs NTLA Comparison
NIE vs NTLA Comparison
Compare NIE & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIE
- NTLA
- Stock Information
- Founded
- NIE 2007
- NTLA 2014
- Country
- NIE United States
- NTLA United States
- Employees
- NIE N/A
- NTLA N/A
- Industry
- NIE Investment Managers
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NIE Finance
- NTLA Health Care
- Exchange
- NIE Nasdaq
- NTLA Nasdaq
- Market Cap
- NIE 697.4M
- NTLA 710.1M
- IPO Year
- NIE N/A
- NTLA 2016
- Fundamental
- Price
- NIE $22.31
- NTLA $8.12
- Analyst Decision
- NIE
- NTLA Buy
- Analyst Count
- NIE 0
- NTLA 19
- Target Price
- NIE N/A
- NTLA $38.26
- AVG Volume (30 Days)
- NIE 70.5K
- NTLA 3.1M
- Earning Date
- NIE 01-01-0001
- NTLA 05-08-2025
- Dividend Yield
- NIE 9.04%
- NTLA N/A
- EPS Growth
- NIE N/A
- NTLA N/A
- EPS
- NIE N/A
- NTLA N/A
- Revenue
- NIE N/A
- NTLA $45,569,000.00
- Revenue This Year
- NIE N/A
- NTLA N/A
- Revenue Next Year
- NIE N/A
- NTLA N/A
- P/E Ratio
- NIE N/A
- NTLA N/A
- Revenue Growth
- NIE N/A
- NTLA N/A
- 52 Week Low
- NIE $18.61
- NTLA $5.90
- 52 Week High
- NIE $22.47
- NTLA $28.18
- Technical
- Relative Strength Index (RSI)
- NIE 57.69
- NTLA 50.39
- Support Level
- NIE $21.92
- NTLA $7.21
- Resistance Level
- NIE $22.50
- NTLA $9.27
- Average True Range (ATR)
- NIE 0.32
- NTLA 0.61
- MACD
- NIE 0.15
- NTLA 0.02
- Stochastic Oscillator
- NIE 90.71
- NTLA 44.20
About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments such as aerospace and defense, banks, IT services, software, and others.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.